Ixazomib Citrate
Brand name: Ninlaro
Rank #176 of 500 drugs by total cost
$89.0M
Total Cost
6,901
Total Claims
$89.0M
Total Cost
348
Prescribers
$13K
Cost per Claim
42
Beneficiaries
6,938
30-Day Fills
$256K
Avg Cost/Provider
20
Avg Claims/Provider
About Ixazomib Citrate
Ixazomib Citrate (sold as Ninlaro) was prescribed 6,901 times by 348 Medicare Part D providers in 2023, costing the program $89.0M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
| 179 | Teduglutide (Gattex) | $88.4M | 1,758 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology